Cargando…

Harm of early dexamethasone for COVID-19 and bias in randomized trials

Detalles Bibliográficos
Autores principales:	Núñez, Isaac, Caro-Vega, Yanink, Soto-Mota, Adrian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Federation of Internal Medicine. Published by Elsevier B.V. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482838/ https://www.ncbi.nlm.nih.gov/pubmed/36150979 http://dx.doi.org/10.1016/j.ejim.2022.09.014

Ejemplares similares

The Early Repetition of Deliberate Self Harm
por: Cohen, Samuel I
Publicado: (1997)

Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen
por: Jacobus, S J, et al.
Publicado: (2016)

Response to: Correspondence on ‘Prospective predictive performance comparison between clinical gestalt and validated COVID-19 mortality scores’ by Meza-Comparán
por: Soto-Mota, Adrian, et al.
Publicado: (2022)

1120. Impact of Training Residents to Improve HIV Screening in a Teaching Hospital in Mexico City
por: Guerrero-Torres, Lorena, et al.
Publicado: (2020)

Dexamethasone for treatment of severe COVID-19, a surprise?
por: Elsayed, Hany Hasan
Publicado: (2020)

Worrying situation regarding the use of dexamethasone for COVID-19
por: Lim, Michael Anthonius, et al.
Publicado: (2020)

Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?
por: Gupta, Rahul
Publicado: (2022)

Hospitalization as an outcome in ambulatory COVID-19 trials—not applicable in every setting
por: Núñez, Isaac, et al.
Publicado: (2022)

Iron chelation may harm patients with COVID-19
por: Garrick, Michael D., et al.
Publicado: (2020)

Antenatal corticosteroids and COVID-19: balancing benefits and harms
por: Liauw, Jessica, et al.
Publicado: (2020)

Dexamethasone and COVID-19 in a Developing Country: Appropriate Use?
por: Marreros, Diego Martin Moreno, et al.
Publicado: (2021)

Reply: Iron chelation may harm patients with COVID-19
por: Abobaker, Anis
Publicado: (2020)

Targeting severe symptoms of early 2023-new outbreak of COVID-19 by classical drug dexamethasone: a potential fatality reducing agent
por: Liu, Dongsheng, et al.
Publicado: (2023)

Colchicine may not be effective in COVID-19 infection; it may even be harmful?
por: Cumhur Cure, Medine, et al.
Publicado: (2020)

Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19
por: Kavanagh, Oisín, et al.
Publicado: (2020)

Non-recommended medical interventions and their possible harm in patients with COVID-19
por: Pecho-Silva, Samuel, et al.
Publicado: (2021)

Systemic corticosteroids for management of COVID-19: Saving lives or causing harm?
por: FakhriRavari, Alireza, et al.
Publicado: (2021)

Dexamethasone Treatment for COVID-19-Related Lung Injury in an Adult with WHIM Syndrome
por: Akahane, Daigo, et al.
Publicado: (2021)

The Harm in Kratom
por: Drago, Joshua Z., et al.
Publicado: (2017)

No Harm Done?
por: Crawford, Mike
Publicado: (1999)

Immortal time bias in retrospective analysis: comment on ‘Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma'
por: Hsieh, P-Y, et al.
Publicado: (2015)

A potential harmful effect of dexamethasone in non-severe COVID-19: results from the COPPER-pilot study
por: Kocks, Janwillem, et al.
Publicado: (2022)

Treatment algorithm with dexamethasone intravitreal implant in patients with diabetic macular edema
por: Epstein, David, et al.
Publicado: (2019)

Novel nicotine products: Averting a harmful revolution
por: Jovell, Laura, et al.
Publicado: (2023)

Comment on “Colchicine may not be effective in COVID-19 infection; it may even be harmful?”
por: Kobak, Senol
Publicado: (2020)

Evaluation of clinical harm associated with Omicron hospital-onset COVID-19 infection
por: Otter, Jonathan A., et al.
Publicado: (2023)

Does Vitamin D have a role to play in Covid-19 in the dexamethasone era?
por: Mandal, Amit KJ., et al.
Publicado: (2021)

Reply: Selection bias in estimates of early pregnancy loss
por: Jacoby, Vanessa L., et al.
Publicado: (2022)

COVID-19: scientific reasoning, pragmatism and emotional bias
por: Gattinoni, Luciano, et al.
Publicado: (2020)

First, do no harm: bilateral radial artery occlusion in a COVID-19 patient
por: Bouwhuis, Anne, et al.
Publicado: (2020)

Impact of COVID-19 on neonatal health: Are we causing more harm than good?
por: Smith, Hazel A.
Publicado: (2020)

Heterogeneity of hypoxemia severity according to pulse oximetry and blood gas analysis in COVID-19 pneumonia
por: Núñez, I., et al.
Publicado: (2022)

Heterogeneity of hypoxemia severity according to pulse oximetry and blood gas analysis in COVID-19 pneumonia
por: Núñez, I., et al.
Publicado: (2022)

Severe COVID-19 along with Cytokine Storm in Pemphigus Vulgaris Managed Successfully with Dexamethasone Pulse Therapy
por: Pradhan, Swetalina, et al.
Publicado: (2021)

Early de-escalation of DAPT after PCI: implications of the latest randomized trials in the COVID era
por: Mahajan, Kunal, et al.
Publicado: (2020)

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial
por: Pettitt, Andrew R., et al.
Publicado: (2020)

Perineal pruritus in epidural dexamethasone injections
por: Veilleux, Catherine, et al.
Publicado: (2019)

Comment on: Effect of sustained-release long-acting intravitreal dexamethasone implant in patients of non-proliferative diabetic retinopathy undergoing phacoemulsification: A randomized controlled trial
por: Panigrahi, Pradeep K
Publicado: (2022)

Challenging cognitive biases in the health system during the COVID-19 pandemic
por: Sacco, A., et al.
Publicado: (2021)

Benefit of OTC Formula Against COVID-19 Is Explained by Selection Bias
por: Hemilä, Harri
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rh3kgo591kcu6g4ph4p0k1kmto